Direxion Daily Magnificent 7 Bull 2X Shares (ARCA: QQQU)

最新ニュース Direxion Daily Magnificent 7 Bull 2X Shares (ARCA:QQQU)

The Fund, under normal circumstances, invests at least 80 percent of its net assets (plus borrowing for investment purposes) in financial instruments, such as swap agreements, securities of the Index, and exchange-traded funds (ETFs) that track the Index, that, in combination, provide 2X daily leveraged exposure to the Index, consistent with the Fund's investment objective. The financial instruments in which the Fund most commonly invests are swap agreements and futures agreements which are intended to produce economically leveraged investment results.

Direxion Daily Concentrated Qs Bull 2X Shares

Direxion Daily Magnificent 7 Bull 2X Shares

The Trump (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">TRUMP</a>) meme coin has plunged 42.6% in the past week, following Donald Trump's tariff announcement—a sharp reversal for the <a href="https://www.benzinga.com/money/trump-coin-price-prediction">high-flying meme crypto</a>.
What Happened: According to Lookonchain, a whale who had pocketed $11.8 million in TRUMP gains in mid-January reinvested his profits, only to see the trade turn against him. 
The whale spent $33.9 million to acquire 766,083 TRUMP at an average price of $44.25, only to suffer a $21 million loss as prices collapsed. 
This move <a href="https://x.com/lookonchain/status/1886704116652810567">erased</a> not only their entire profit but also $9 million of the original capital.
Despite this steep drop, data from Merkle Science and Chainalysis, cited by Reuters, shows TRUMP having generated $100 million in trading fees in less than two weeks, highlighting continued high-volume activity.
Once the best-performing meme coin before the tariff news, TRUMP has now lost nearly 50% of its total valuation in just days.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/02/43430801/exclusive-anthony-scaramucci-warns-donald-trumps-crypto-promises-may-be-a-mirage">EXCLUSIVE: Anthony Scaramucci Warns Donald Trump&#8217;s Crypto Promises May Be A &#8216;Mirage&#8217;</a>
What's Next: Trader Johnny believes buying TRUMP under $20 will be seen as a bargain in the coming months, predicting that it will ultimately reach new all-time highs.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">I think buying <a href="https://twitter.com/search?q=%24TRUMP&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$TRUMP</a> sub $20 will be looked as a steal a few months from now Expecting this to go to new ATH&#39;s at some point <a href="https://t.co/6DDkqvUoUf">pic.twitter.com/6DDkqvUoUf</a>
&mdash; Johnny (@CryptoGodJohn) <a href="https://twitter.com/CryptoGodJohn/status/1886434777340739764?ref_src=twsrc%5Etfw">February 3, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Rodney, another crypto trader, <a href="https://x.com/cryptojourneyrs/status/1886425944942113031">notes</a> that despite the crash, TRUMP still holds the fourth position among meme coins, urging investors to stay patient for a recovery.
Trader Viktor <a href="https://x.com/thedefivillain/status/1886712178654503130">argues</a> that while the TRUMP and MELANIA meme coins were attractive short hedges, the risk/reward dynamics have now shifted.
He describes TRUMP as a low beta bleeding coin with many underwater bagholders, but also points out that liquidity is so thick that volatility has decreased.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/01/43390075/department-of-government-efficiency-meme-coin-plummets-30-as-attention-pivots-to-trump">Department Of Government Efficiency Meme Coin Plummets 30% As Attention Pivots To TRUMP</a></li>
</ul>
Image created using artificial intelligence with Midjourney.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

News

$TRUMP

TRUMP Meme Coin Down 42% In A Week: How Low Can It Go?

Rosenblatt analyst Kevin Cassidy maintains Synaptics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYNA#NASDAQ">SYNA</a>) with a Buy and maintains $92 price target.

Price Target

Analyst Ratings

SYNA

Rosenblatt Maintains Buy on Synaptics, Maintains $92 Price Target

Financing

ACON

Aclarion Secures Funding For Its CLARITY Trial For Nociscan

Keefe, Bruyette &amp; Woods analyst Meyer Shields maintains RenaissanceRe Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RNR#NYSE">RNR</a>) with a Outperform and lowers the price target from $318 to $294.

Keefe, Bruyette & Woods Maintains Outperform on RenaissanceRe Holdings, Lowers Price Target to $294

Rosenblatt analyst Mike Genovese maintains Fabrinet (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FN#NYSE">FN</a>) with a Buy and raises the price target from $280 to $285.

Rosenblatt Maintains Buy on Fabrinet, Raises Price Target to $285

Rosenblatt analyst Kevin Cassidy maintains Rambus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMBS#NASDAQ">RMBS</a>) with a Buy and raises the price target from $85 to $92.

RMBS

Rosenblatt Maintains Buy on Rambus, Raises Price Target to $92

Baird analyst Eric Coldwell maintains Owens &amp; Minor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OMI#NYSE">OMI</a>) with a Neutral and lowers the price target from $15 to $14.

Baird Maintains Neutral on Owens & Minor, Lowers Price Target to $14

Additionally, the Company expects its financial performance for each of the remaining measures that it previously issued guidance for to be at or above the high-end of the previously announced ranges.

Guidance

GETY

Getty Images Expects Q4 Revenue Of $244M - $250M (Est $244.99M), Revises 2024 Revenue Outlook From $934M - $943M To $936M - $942M (Est $937.01M)

Coloplast (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CLPBY#OTC">CLPBY</a>) FY25 Reported Revenue growth expected to be 8-9% YoY from DKK 27,030M

CLPBY

Coloplast FY25 Reported Revenue growth expected to be 8-9% YoY from DKK 27,030M

Telsey Advisory Group analyst Dana Telsey maintains Ralph Lauren (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RL#NYSE">RL</a>) with a Outperform and maintains $265 price target.

Telsey Advisory Group Maintains Outperform on Ralph Lauren, Maintains $265 Price Target

Mizuho analyst Matthew Broome maintains Palantir Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>) with a Underperform and raises the price target from $44 to $80.

PLTR

Mizuho Maintains Underperform on Palantir Technologies, Raises Price Target to $80

TransDigm Reaffirms FY25 Sales Outlook Of $8.75B - $8.95B Vs. $8.9B Est; EBITDA Of $4.615B - $4.755B.

Barclays analyst Richard Hightower maintains Agree Realty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADC#NYSE">ADC</a>) with a Underweight and lowers the price target from $76 to $74.

Barclays Maintains Underweight on Agree Realty, Lowers Price Target to $74

McEwen Mining (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MUX#NYSE">MUX</a>) has significantly expanded the gold resource at its Grey Fox deposit, part of the Fox Complex in Northern Ontario.
Since the last estimate in 2021, Grey Fox's indicated gold resource has increased by 32% to 1.54 million ounces, while inferred resources have nearly doubled to 458,000 ounces. The <a target="_blank" href="https://www.benzinga.com/topic/gold" rel="noreferrer noopener">total gold resource</a> has grown by nearly 50% over three years.
"Our investment in exploration on the Fox Complex properties has successfully expanded our gold resources, which will enable us to both increase annual production and extend the mine life," <a target="_blank" href="https://www.mcewenmining.com/investor-relations/press-releases/press-release-details/2025/McEwen-MiningGrey-Fox-Gold-Resources-Hit-a-Significant-Milestone/default.aspx" rel="noreferrer noopener">said</a> Chairman Rob McEwen.
The company credits its success to extensive exploration drilling and higher gold prices. The $2,000 per ounce calculation allowed for a lower cut-off grade, from 2.30 g/t Au to 1.60 g/t Au.
The Grey Fox deposit is located approximately 3 kilometers southeast of McEwen's Black Fox Mine and 75 kilometers east of Timmins, Ontario. It lies within the prolific Porcupine-Destor Fault Zone, a region historically associated with over 110 million ounces of gold production.
The deposit consists of six zones, with the Gibson zone showing the most significant growth—its indicated resources increased by 181% to 290,000 ounces, while inferred resources rose by 80% to 245,000 ounces. The Whiskey-Jack zone also stands out, with 97% of its mineralization categorized as indicated, totaling 116,000 ounces at a high grade of 5.7 g/t.
The discovery cost for the increased resources was remarkably low at $14.46 per ounce, aligned with the firm's cost-conscious approach.
The firm has outlined its production and cost guidance for 2025. The company expects consolidated production to range between 120,000 and 140,000 gold equivalent ounces (GEOs) – similar to FY 2024 production, which achieved 135,900 GEOs.
The lower end of the range reflects the planned transition from the Froome mine to the Stock mine at the Fox Complex, with commercial production from Stock anticipated in early 2026.
Despite permitting delays, McEwen remains confident in its long-term strategy to enhance production and extend the mine life at its Fox Complex, supported by the continued growth of resources at Grey Fox and other deposits.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43430259/miners-plead-for-collaboration-as-trade-wars-threaten-critical-mineral-supply-chains" target="_blank" rel="noreferrer noopener">Miners Plead For Collaboration As Trade Wars Threaten Critical Mineral Supply Chains</a></li>
</ul>
Image via Shutterstock

Commodities

Markets

McEwen Boosts Grey Fox Resources, Issues 2025 Guidance

As part of this effort, Getty Images will seek to amend its existing credit agreement to refinance its existing term loan facilities with the dollar equivalent of up to $1.05 billion of replacement term loan term facilities. The strategic refinancing is intended to, among other things, extend existing term loan maturities.

Getty Images Launches Process To Refinance Outstanding Senior Secured Term Loan Facilities, Which Are Scheduled To Mature On February 19, 2026 - Filing

TransDigm Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDG#NYSE">TDG</a>) reported quarterly adjusted earnings of $7.83 per share which beat the analyst consensus estimate of $7.65 by 2.35 percent. This is a 9.36 percent increase over earnings of $7.16 per share from the same period last year. The company reported quarterly sales of $2.01 billion which missed the analyst consensus estimate of $2.03 billion by 1.21 percent. This is a 12.13 percent increase over sales of $1.79 billion the same period last year.

Earnings

Earnings Beats

Earnings Misses

TransDigm Gr Q1 Adj $7.83 Beats $7.65 Estimate, Sales $2.01B Miss $2.03B Estimate

WIIM

QNTM

Quantum BioPharma shares are trading higher after the company announced positive clinical trial results for its unbuzzd dietary supplement, showing it accelerated the reduction of blood alcohol concentration.

Janney Montgomery Scott analyst Jake Civiello upgrades Princeton Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPRN#NASDAQ">BPRN</a>) from Neutral to Buy and announces $35 price target.

Upgrades

BPRN

Janney Montgomery Scott Upgrades Princeton Bancorp to Buy, Announces $35 Price Target

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector.
<h3 class="wp-block-heading">Premier, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PINC#NASDAQ">PINC</a>)</h3>
<ul>
<li>Dividend Yield: 3.75%</li>
<li>Baird analyst Eric Coldwell maintained a Neutral rating and raised the price target from $19 to $20 on Nov. 6, 2024. This analyst has an accuracy rate of 60%.</li>
<li>Benchmark analyst Bill Sutherland downgraded the stock from Buy to Hold on Aug. 26, 2024. This analyst has an accuracy rate of 69%.</li>
<li>Recent News: On Feb. 4, Premier posted downbeat quarterly results.</li>
<li>Benzinga Pro's real-time newsfeed alerted to latest PINC <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent020425&amp;t=be2bearmibe3na1">news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent020425&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="887" height="822" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04071132/image-20.png" alt="" class="wp-image-764631" style="width:544px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04071132/image-20.png 887w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04071132/image-20-300x278.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04071132/image-20-768x712.png 768w" sizes="(max-width: 887px) 100vw, 887px" /></a></figure>
<h3 class="wp-block-heading">Bristol-Myers Squibb Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>)</h3>
<ul>
<li>Dividend Yield: 4.14%</li>
<li>Citigroup analyst Andrew Baum maintained a Neutral rating and raised the price target from $60 to $65 on Jan. 28. This analyst has an accuracy rate of 71%.</li>
<li>B of A Securities analyst Tim Anderson reinstated a Neutral rating with a price target of $63 on Dec. 10, 2024. This analyst has an accuracy rate of 62%.</li>
<li>Recent News: On Jan. 31, Bristol Myers Squibb received positive CHMP opinion for Opdivo&#xAE; (nivolumab) plus Yervoy&#xAE; (ipilimumab) as a first-line treatment option for adult patients with unresectable or advanced hepatocellular carcinoma.</li>
<li>Benzinga Pro's real-time newsfeed alerted to latest <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent020425&amp;t=be2bearmibe3na1">BMY news</a> </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent020425&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="900" height="827" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04071205/image-21.png" alt="" class="wp-image-764633" style="width:691px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04071205/image-21.png 900w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04071205/image-21-300x276.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04071205/image-21-768x706.png 768w" sizes="(max-width: 900px) 100vw, 900px" /></a></figure>
<h3 class="wp-block-heading">CVS Health Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>)</h3>
<ul>
<li>Dividend Yield: 4.75%</li>
<li>Truist Securities analyst David Macdonald maintained a Buy rating and cut the price target from $67 to $60 on Jan. 6. This analyst has an accuracy rate of 68%.</li>
<li>Deutsche Bank analyst George Hill upgraded the stock from Hold to Buy with a price target of $66 on Dec. 3, 2024. This analyst has an accuracy rate of 60%.</li>
<li>Recent News: CVS Health will hold a conference call on Wednesday, Feb. 12, to discuss fourth quarter and full year 2024 financial results.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to latest CVS <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent020425&amp;t=be2bearmibe3na1">news </a></li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent020425&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="902" height="835" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04071237/image-22.png" alt="" class="wp-image-764635" style="width:594px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04071237/image-22.png 902w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04071237/image-22-300x278.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04071237/image-22-768x711.png 768w" sizes="(max-width: 902px) 100vw, 902px" /></a></figure>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More:
<ul>
<li><a href="https://www.benzinga.com/25/02/43432950/jim-cramer-appfolio-is-a-cheap-stock-dont-sell-this-tech-stock"> Jim Cramer Says AppFolio Is A &#8216;Good One,&#8217; But Summit Therapeutics? &#8216;Can&#8217;t Go There&#8217;</a></li>
</ul>

Comments

Direxion Daily Magnificent 7 Bull 2X Shares

ニュース

最新ニュース Direxion Daily Magnificent 7 Bull 2X Shares (ARCA:QQQU)

ニュース

パートナーシップ

ベンジンガ・グローバル